Rare Disease AdvisorBreast Milk-Mediated Hemolysis Found as Cause of Delayed HDFN

⚠️ Small Study / Early Comparative Evidence

Investigators reported the case of a 50-day-old infant with severe RhD-mediated hemolytic disease of the fetus and newborn (HDFN) who continued to experience significant anemia and jaundice despite prior successful exchange transfusion. Testing demonstrated high-titer anti-RhD IgG antibodies in maternal breast milk, raising concern for continued passive antibody transfer after birth.

Clinical Considerations

• The infant presented with severe anemia, jaundice, and a strongly positive direct antiglobulin test.
• Maternal serum anti-D antibody titers remained markedly elevated (1024), while the infant’s plasma titer measured only 2.
• Breast milk analysis confirmed the presence of high-titer anti-RhD IgG antibodies.
• Following transition to formula feeding, hemoglobin levels improved substantially and bilirubin concentrations declined.
• By day 116 of life, laboratory abnormalities had normalized and hemolysis had resolved.
• The report suggests breast milk-mediated transfer of maternal alloantibodies may contribute to prolonged or unexplained hemolysis in select infants of alloimmunized mothers.

Practice Applications

• Persistent anemia or jaundice beyond the expected neonatal course in infants with known maternal alloimmunization may warrant consideration of ongoing passive antibody exposure.
• Maternal breast milk represents a potential, though likely uncommon, source of antibody transfer requiring additional investigation.
• Clinicians should recognize that this observation derives from a single case report and should not alter standard breastfeeding recommendations without broader supporting evidence.
• Further studies are needed to determine the frequency, clinical significance, and management implications of breast milk-mediated alloantibody transfer.